237 related articles for article (PubMed ID: 25491042)
1. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.
Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
J Oncol Pract; 2015 Jan; 11(1):47-54. PubMed ID: 25491042
[TBL] [Abstract][Full Text] [Related]
2. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
[TBL] [Abstract][Full Text] [Related]
3. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.
Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
Support Care Cancer; 2014 Dec; 22(12):3275-85. PubMed ID: 25082364
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
5. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
6. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
Flanigan JA; Yasuda M; Chen CC; Li EC
Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
[TBL] [Abstract][Full Text] [Related]
8. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
[TBL] [Abstract][Full Text] [Related]
10. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
12. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
[TBL] [Abstract][Full Text] [Related]
13. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
15. Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.
Weycker D; Chandler D; Barron R; Xu H; Wu H; Edelsberg J; Lyman GH
J Oncol Pharm Pract; 2017 Jan; 23(1):33-42. PubMed ID: 26568602
[TBL] [Abstract][Full Text] [Related]
16. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
17. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.
Pathak R; Giri S; Aryal MR; Karmacharya P; Bhatt VR; Martin MG
Support Care Cancer; 2015 Mar; 23(3):615-7. PubMed ID: 25556610
[TBL] [Abstract][Full Text] [Related]
18. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
19. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The
Aagaard T; Reekie J; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
Int J Cancer; 2020 Jan; 146(2):321-328. PubMed ID: 30839100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]